9 hrs ago
Optical coherence tomography in primary percutaneous coronary intervention
The first randomized trial to examine serial optical coherence tomography in primary percutaneous coronary intervention was reported today at the 26th annual Transcatheter Cardiovascular Therapeutics scientific symposium. Sponsored by the Cardiovascular Research Foundation , TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
A stent is a small mesh tube that s used to treat narrow or weak arteries.
Yet more than five years later, all seven developed dangerous blood clots and came to Thomas Jefferson University Hospital with heart attacks. The common thread? All of them either had stopped taking aspirin, were actively smoking, or both, according to a new report by Jefferson physicians.
Efficacy of two different self-expanding nitinol stents for...
Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease : study protocol for a randomized controlled trial Sang Ho Park , Seung Woon Rha , Cheol Ung Choi , Eung Ju Kim , Dong Joo Oh , Yun Hyeong Cho , Woong Gil Choi , Seung Jin Lee , Yong Hoon Kim , Seung Hyuk Choi , Won Ho Kim , Ki Chang Kim , Jang Hyun Cho , Joo Han Kim , Sang Min Kim , Jang Ho Bae , Jung Min Bong , Won Yu Kang , Ju Yeol Baek , Jae Bin Seo , Woo Young Chung , Mahn Won Park , Sung Ho Her , Jon Suh , Min Woong Kim , Yeo Joo Kim , Hwan Jun Choi and Jae Wan Soh There have been few randomized control trials comparing the incidence of stent fracture and primary patency among different self-expanding nitinol stents to date.
Advancement Of Ascendia Pharmaceuticals??'s Nano-Emulsion Technology...
Ascendia Pharmaceuticals, a start-up specialty pharmaceutical company in the business of providing formulation technologies and product development services for poorly soluble molecules, today announced that the company has successfully applied its nano-emulsion technology platform to a novel injectable formulation of clopidogrel - the world's top-selling blood thinner medicine. Ascendia has advanced the program to pre-IND development stage, and has filed US and worldwide PCT patent applications on the product.
View Press Release
Ascendia has advanced the program to pre-IND development stage, and has filed US and worldwide PCT patent applications on the product. "There is a significant unmet medical need for a parenteral clopidogrel dosage form for the treatment of Acute Coronary Syndrome under life-threatening situations," said Jingjun "Jim" Huang, Ph.D ., CEO of Ascendia.
Racial Differences in Resistance to P2Y12 Receptor Antagonists in Type 2 Diabetic Subjects.
Although resistance to the P2Y12 antagonist clopidogrel is linked to altered drug metabolism, some studies suggest that these pharmacokinetic abnormalities only partially account for drug resistance.
Ambulance administration of anti-clot drug may benefit heart attack patients
Ambulance administration of the antiplatelet medication ticagrelor to patients with a type of heart attack known as ST segment elevation myocardial infarction is not better than hospital administration, in terms of improving blood flow in blocked arteries before a revascularisation procedure, according to a new study presented at ESC Congress 2014 ... (more)
Mangalam Drugs and Organics Limited (MANGALAM) - Financial and...
Mangalam Drugs and Organics Limited is a chemical company, based in India. The company manufactures chemicals such as API, Perfumery Chemicals, and Disperse Dye Intermediates at Gujarat.
Response to Letter Regarding, "Administration of a Loading Dose Has...
The novel antiplatelet agent, ticagrelor, has several advantages over the long-standing clopidogrel, as the virtual absence of nonresponders and the more powerful platelet inhibition.
AstraZeneca says DOJ closes probe into drug trial
British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.
Top News: Pound Falls To Four-Month Low As Uk Inflation Slows To 1.6%
BHP Billiton PLC confirmed that it will demerge its aluminium, coal, manganese, nickel and silver assets into a new company, pledging to cut costs and improve the productivity of its remaining businesses in an attempt to boost shareholder returns.
Letter by Zhang Regarding Article, "Early Dual Versus Mono...
I have read "Early Dual Versus Mono Antiplatelet Therapy for Acute Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack: An Updated Systematic Review and Meta-Analysis" by Wong and colleagues with great interest.